Recent content by Michael Larsen

Some news from Minbo Shim http://cmclinics.com/

http://www.bionure.com/news/bionure-initiates-a-phase-1-clinical-trial-of-its-lead-compound-bn201-in-the-united-kingdom About BN201 and BN119 Bionure’s compounds BN201 and BN119 are two SGK agonists with remyelinating and neuroprotective activity. Bionure has developed BN201 for the treatment...

http://www.dtu.dk/english/news/2018/01/novo-nordisk-foundation-awards-eur-6-million-to-health-research?id=26f52542-03c7-4eac-8000-cfc36a0b2125

Directly from Dong-Kee Kim Dear Larsen, Thank you for your interest in my paper. I think the delivery of small molecular drugs like steroid or antioxidant, is likely to be commercialized within 10 years. However, it is difficult to predict the timing of delivery of genes or a growth factor...

Nano technology Delivery of small molecular drugs like steroid or antioxidant, is likely to be commercialized within 10 years. However, it is difficult to predict the timing of delivery of genes or a growth factor. It may take decades

http://investors.otonomy.com/phoenix.zhtml?c=234082&p=irol-newsArticle_Print&ID=2325672 Developing OTO-313, an improved formulation of gacyclidine for the treatment of tinnitus. Gacyclidine is a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, a molecular class with...

http://investors.otonomy.com/phoenix.zhtml?c=234082&p=irol-newsArticle_Print&ID=2325672 OTO-413 is a sustained exposure formulation of BDNF that has been advanced into IND-enabling activities for the treatment of hidden hearing loss. OTO-413 is a proprietary formulation of brain-derived...

https://autifony.com/ Boehringer Ingelheim and Autifony Therapeutics Limited (“Autifony”) today announced that they have signed an agreement about certain aspects of Autifony’s voltage gated potassium channel modulator platform. Boehringer Ingelheim now has an exclusive option to purchase...

Spiral Therapeutics Receives Positive IND Submission Guidance from FDA LPT99 is currently being tested for the treatment of other hearing loss indications, including noise-induced hearing loss and age-related hearing loss. Clinical trials for LPT99 will begin in early 2018...

http://www.isiet2017.org/ This could be interesting :)

Prof. Tzounopoulos, looking for a new employee, perhaps a good sign https://jobs.sciencecareers.org/job/461538/systems-and-behavioral-auditory-neuroscience/

http://www.express.co.uk/life-style/health/847759/ear-tinnitus-treatment-brain-area-symptoms

Yes and when the help came, it was too late for most people

It sounds something that Josef Rauschecker has said (y)

Yes and perhaps AF243 also could help with synapses restoration right?